Last reviewed · How we verify
NCT03094221
Clinical Utility and Validation of the Rhythmia Mapping System for the Treatment of Cardiac Arrhythmias
trial testing Rhythmia Mapping System in Cardiac Arrhythmias in 20 participants. Completed in 1 December 2015.
1 December 2015
Quick facts
| Lead sponsor | Beth Israel Deaconess Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 13 January 2015 |
| Primary completion | 1 December 2015 |
| Estimated completion | 1 December 2015 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Rhythmia Mapping System
Conditions studied
- Cardiac Arrhythmias — all drugs for Cardiac Arrhythmias →
- Electroanatomic Mapping — all drugs for Electroanatomic Mapping →
- Cardiac Ablation — all drugs for Cardiac Ablation →
Sponsor
Beth Israel Deaconess Medical Center
Who can join
18 and older, any sex, with Cardiac Arrhythmias or Electroanatomic Mapping. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare two different types of three-dimensional electroanatomic mapping systems used for the treatment of cardiac arrhythmias. The systems will be compared in regards to its ability to successfully map and ablate a clinical arrhythmia, as well as the time invested in this activity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03094221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Arrhythmias
Currently open trials in the same condition.
- NCT07020910 — Bad Berka Heart Rhythm Registry of Patients With or at Risk of Arrhythmias Treated at Heart Center Bad Berka · recruiting
- NCT05724121 — Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax · recruiting
- NCT06908369 — Cardiac Symptoms in Patients With Treated Graves' Disease · active not recruiting
- NCT03505801 — Confirm Rx Insertable Cardiac Monitor SMART Registry · active not recruiting
- NCT06898307 — Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: · recruiting
Other Beth Israel Deaconess Medical Center trials
Trials by the same sponsor.
- NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase) · NA · not yet recruiting
- NCT07531602 — Effect of PEEP on Cardiac Function · NA · not yet recruiting
- NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
- NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study · NA · enrolling by invitation
- NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03094221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
- Last refreshed: 29 March 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03094221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing